Immunotherapy in pediatric B-cell acute lymphoblastic leukemia

Kirk D. Wyatt, Richard J Bram

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Advances in multi-agent chemotherapy and supportive care have dramatically improved survival of children with B-cell acute lymphoblastic leukemia (B-ALL); however, patients with relapsed and refractory disease continue to represent a therapeutic challenge. Hematopoietic stem cell transplant was the first immunotherapeutic approach to be used in the treatment of patients with relapsed or refractory disease. However, novel therapies such as bispecific antibodies that engage T-cells and chimeric antigen receptor T-cells (CAR-T) therapy have emerged as novel FDA-approved options that have the potential to become the new standard of care for these difficult-to-treat leukemias. With multiple immunotherapeutic agents in the drug development pipeline, it is important for cancer researchers and oncologists to be familiar with these agents, including their mechanism of action, side effects and efficacy. In this paper, we review the role of the human immune system in the development and treatment of childhood ALL and provide an overview of current and upcoming immunotherapeutic treatment approaches.

Original languageEnglish (US)
JournalHuman Immunology
DOIs
StatePublished - Jan 1 2019

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Immunotherapy
B-Lymphocytes
Pediatrics
Bispecific Antibodies
Therapeutics
Standard of Care
Cell- and Tissue-Based Therapy
Hematopoietic Stem Cells
T-Cell Antigen Receptor
Immune System
Leukemia
Research Personnel
T-Lymphocytes
Transplants
Drug Therapy
Survival
Pharmaceutical Preparations
Neoplasms

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Immunotherapy in pediatric B-cell acute lymphoblastic leukemia. / Wyatt, Kirk D.; Bram, Richard J.

In: Human Immunology, 01.01.2019.

Research output: Contribution to journalReview article

@article{917e93e1fccb4060ace8871213bf6d2a,
title = "Immunotherapy in pediatric B-cell acute lymphoblastic leukemia",
abstract = "Advances in multi-agent chemotherapy and supportive care have dramatically improved survival of children with B-cell acute lymphoblastic leukemia (B-ALL); however, patients with relapsed and refractory disease continue to represent a therapeutic challenge. Hematopoietic stem cell transplant was the first immunotherapeutic approach to be used in the treatment of patients with relapsed or refractory disease. However, novel therapies such as bispecific antibodies that engage T-cells and chimeric antigen receptor T-cells (CAR-T) therapy have emerged as novel FDA-approved options that have the potential to become the new standard of care for these difficult-to-treat leukemias. With multiple immunotherapeutic agents in the drug development pipeline, it is important for cancer researchers and oncologists to be familiar with these agents, including their mechanism of action, side effects and efficacy. In this paper, we review the role of the human immune system in the development and treatment of childhood ALL and provide an overview of current and upcoming immunotherapeutic treatment approaches.",
author = "Wyatt, {Kirk D.} and Bram, {Richard J}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.humimm.2019.01.011",
language = "English (US)",
journal = "Human Immunology",
issn = "0198-8859",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Immunotherapy in pediatric B-cell acute lymphoblastic leukemia

AU - Wyatt, Kirk D.

AU - Bram, Richard J

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Advances in multi-agent chemotherapy and supportive care have dramatically improved survival of children with B-cell acute lymphoblastic leukemia (B-ALL); however, patients with relapsed and refractory disease continue to represent a therapeutic challenge. Hematopoietic stem cell transplant was the first immunotherapeutic approach to be used in the treatment of patients with relapsed or refractory disease. However, novel therapies such as bispecific antibodies that engage T-cells and chimeric antigen receptor T-cells (CAR-T) therapy have emerged as novel FDA-approved options that have the potential to become the new standard of care for these difficult-to-treat leukemias. With multiple immunotherapeutic agents in the drug development pipeline, it is important for cancer researchers and oncologists to be familiar with these agents, including their mechanism of action, side effects and efficacy. In this paper, we review the role of the human immune system in the development and treatment of childhood ALL and provide an overview of current and upcoming immunotherapeutic treatment approaches.

AB - Advances in multi-agent chemotherapy and supportive care have dramatically improved survival of children with B-cell acute lymphoblastic leukemia (B-ALL); however, patients with relapsed and refractory disease continue to represent a therapeutic challenge. Hematopoietic stem cell transplant was the first immunotherapeutic approach to be used in the treatment of patients with relapsed or refractory disease. However, novel therapies such as bispecific antibodies that engage T-cells and chimeric antigen receptor T-cells (CAR-T) therapy have emerged as novel FDA-approved options that have the potential to become the new standard of care for these difficult-to-treat leukemias. With multiple immunotherapeutic agents in the drug development pipeline, it is important for cancer researchers and oncologists to be familiar with these agents, including their mechanism of action, side effects and efficacy. In this paper, we review the role of the human immune system in the development and treatment of childhood ALL and provide an overview of current and upcoming immunotherapeutic treatment approaches.

UR - http://www.scopus.com/inward/record.url?scp=85061355313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061355313&partnerID=8YFLogxK

U2 - 10.1016/j.humimm.2019.01.011

DO - 10.1016/j.humimm.2019.01.011

M3 - Review article

C2 - 30716352

AN - SCOPUS:85061355313

JO - Human Immunology

JF - Human Immunology

SN - 0198-8859

ER -